Login to Your Account



Genmab Lands $1.1B Cancer Deal with 'Perfect Partner' J&J

By Nuala Moran
Staff Writer

Wednesday, September 5, 2012
LONDON – Genmab A/S signed up a "dream partner" last week for its anti-CD38 monoclonal antibody daratumumab, agreeing a worldwide commercialization deal with Janssen Biotech Inc., with a total potential value of more than $1.1 billion, of which $135 million is to be paid up front.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription